Expanded Access for Apixaban

Purpose

This is an expanded access designed to provide access to apixaban for eligible participants.

Eligibility

Eligible Ages
Between 28 Days and 17 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Pediatric patients with Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention - Previously participated in the CV185-362 study and was on apixaban for 1 year or until treatment was no longer required

Exclusion Criteria

  • Weight less than 5 kg or greater than 35 kg Other inclusion/exclusion criteria apply

Study Design

Phase
Study Type
Expanded Access

Recruiting Locations

Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania 19104
Contact:
Andrew Glatz, Site 0001

More Details

Status
Available
Sponsor
Bristol-Myers Squibb

Study Contact

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
please email:
Clinical.Trials@bms.com